Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Baxter International Inc (BAX) vs Cardinal Health Inc (CAH) Price & Performance

Baxter International IncTrade
Cardinal Health IncTrade

Price performance (Past 24H)

Key statistics

Baxter International Inc vs Cardinal Health Inc — how do they compare? Baxter International Inc trades at $27.27 (market cap $14.27B), while Cardinal Health Inc trades at $238.2 (market cap $55.88B). The key difference: Cardinal Health Inc is far larger — about 3.9× Baxter International Inc's market cap, and Cardinal Health Inc pays the higher dividend (0.86%). Which is the better fit depends on your goals.

BAXCAH
Market Cap
$14.27B$55.88B
Sector
HealthHealth
52-Week High
$28.35$240.26
52-Week Low
$15.80$146.04
Enterprise Value
$21.79B$59.91B
Dividend Yield
0.14%0.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Baxter International Inc

Baxter International Inc. (BAX) trades at $27.78, up 0.83% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.56 versus $0.37 expected, and revenue guidance was raised, signaling operational improvement. However, the company posted a net loss of -$957 million in 2025, with negative profit margins and high P/E of 87.85, reflecting valuation concerns amid turnaround efforts.

The stock shows potential from earnings momentum and cost initiatives, but high debt and inconsistent profitability pose risks. Analyst consensus is mixed with a $25.43 price target below current levels, suggesting cautious optimism. Investors should weigh recent beats against structural challenges in the medtech sector.

Cardinal Health Inc

Cardinal Health (CAH) trades at $237.18, up 0.33% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue reached $222.58 billion in 2025, with net income margin improving to 0.67%. Positive sentiment is driven by strong Q4 2026 results and optimistic fiscal 2027 guidance highlighted by Reuters on August 11, 2026.

Outlook remains favorable with analyst consensus price target of $266.43 implying 12% upside. Key opportunities include pharmaceutical segment strength and dividend payments, while risks involve high debt levels and thin profit margins. The bullish analyst stance (54.55% buy ratings) supports growth potential, but investors should monitor cash flow volatility and competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Baxter International Inc

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.

Read more on BAX

About Cardinal Health Inc

Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.

Read more on CAH